We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

86 hedge funds and large institutions have $332M invested in CytomX Therapeutics in 2017 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 3

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

79% more capital invested

Capital invested by funds: $185M → $332M (+$146M)

45% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 20

26% more funds holding

Funds holding: 68 → 86 (+18)

6.08% more ownership

Funds ownership: 46.31% → 52.39% (+6.1%)

Holders
86
Holders Change
+18
Holders Change %
+26.47%
% of All Funds
2.14%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.1%
New
27
Increased
29
Reduced
20
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$16.4M
2
BlackRock
BlackRock
New York
+$13.2M
3
EC
EcoR1 Capital
California
+$10.5M
4
PA
Perceptive Advisors
New York
+$7.99M
5
DCM
Driehaus Capital Management
Illinois
+$3.88M

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$17M
2
VMI
VHCP Management II
New York
-$3.8M
3
TCM
Tekla Capital Management
Massachusetts
-$2.97M
4
CAM
Cormorant Asset Management
Massachusetts
-$1.86M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$696K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$2.56M -$696K -52,898 -26%
MBT
27
Montecito Bank & Trust
California
$2.53M – – –
SIM
28
Spark Investment Management
New York
$1.76M +$461K +35,000 +52%
Charles Schwab
29
Charles Schwab
California
$1.73M +$65.3K +4,959 +5%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.49M -$5.33K -405 -0.5%
Bank of America
31
Bank of America
North Carolina
$1.35M -$523K -39,767 -34%
VIA
32
Vident Investment Advisory
Georgia
$1.31M +$167K +12,652 +20%
IHM
33
Iguana Healthcare Management
New York
$1.29M +$987K +75,000 New
PI
34
Putnam Investments
Massachusetts
$1.29M -$17M -1,289,673 -95%
LCM
35
Landscape Capital Management
New Jersey
$1.23M +$934K +70,943 New
ROTUOC
36
Regents of the University of California
California
$1.22M +$302K +22,918 +48%
TI
37
Trexquant Investment
Connecticut
$1.05M +$580K +44,079 +261%
TCIM
38
TIAA CREF Investment Management
New York
$1.03M -$80.8K -6,141 -9%
Morgan Stanley
39
Morgan Stanley
New York
$916K -$141K -10,692 -17%
MIM
40
Monashee Investment Management
Massachusetts
$798K – – –
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$695K -$23.7K -1,800 -4%
TA
42
Teachers Advisors
New York
$604K – – –
CLCM
43
Crawford Lake Capital Management
New Jersey
$604K +$461K +35,000 New
HCM
44
Highbridge Capital Management
New York
$598K +$266K +20,246 +141%
AllianceBernstein
45
AllianceBernstein
Tennessee
$598K +$455K +34,600 New
OAM
46
Oxford Asset Management
United Kingdom
$547K +$92.1K +6,995 +28%
Invesco
47
Invesco
Georgia
$534K +$407K +30,925 New
Prudential Financial
48
Prudential Financial
New Jersey
$485K +$369K +28,070 New
Deutsche Bank
49
Deutsche Bank
Germany
$482K +$205K +15,572 +126%
Swiss National Bank
50
Swiss National Bank
Switzerland
$463K +$56.6K +4,300 +19%
1
2
3 4

CTMX Hedge Fund Activity: Q1 2017 in Review

86 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2017, worth a combined $332M — up 79% from $185M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CTMX positions and 3 closed out — a net gain of 24 holders — while 29 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, adding an estimated $16.4M. The largest seller was Putnam Investments, cutting an estimated $17M.

  • 86 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2017, up from 68 in Q4 2016.
  • Funds reported $332M of CytomX Therapeutics stock for Q1 2017, up 79% quarter-over-quarter.
  • 27 funds opened new CytomX Therapeutics positions in Q1 2017 and 3 closed out, a net change of +24 holders.
  • The largest CytomX Therapeutics buyer in Q1 2017 was BVF Inc, an estimated $16.4M added.
  • The largest CytomX Therapeutics seller in Q1 2017 was Putnam Investments, an estimated $17M sold.

Based on aggregated 13F filings for Q1 2017.